Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Treasury Shares (2016 - 2026)

United Therapeutics' Treasury Shares history spans 17 years, with the latest figure at $4.3 billion for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 22.62% to $4.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.3 billion, a 22.62% increase, with the full-year FY2025 number at $4.3 billion, up 22.62% from a year prior.
  • Treasury Shares hit $1.4 million in Q4 2025 for United Therapeutics, down from $32.8 million in the prior quarter.
  • Over the last five years, Treasury Shares for UTHR hit a ceiling of $32.8 million in Q3 2025 and a floor of $181772.0 in Q2 2024.
  • Historically, Treasury Shares has averaged $17.2 million across 5 years, with a median of $26.6 million in 2021.
  • Biggest five-year swings in Treasury Shares: changed 0.0% in 2021 and later surged 34.74% in 2024.
  • Tracing UTHR's Treasury Shares over 5 years: stood at $2.6 billion in 2021, then changed by 0.0% to $2.6 billion in 2022, then changed by 0.0% to $2.6 billion in 2023, then soared by 34.71% to $3.5 billion in 2024, then rose by 22.62% to $4.3 billion in 2025.
  • Business Quant data shows Treasury Shares for UTHR at $4.3 billion in Q4 2025, $4.3 billion in Q3 2025, and $3.5 billion in Q2 2025.